Drug
Astugenal
Astugenal is a pharmaceutical drug with 3 clinical trials. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_3
2
67%
Ph phase_2
1
33%
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
2(66.7%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Not yet recruiting2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (33.3%)
Phase 32 (66.7%)
Trials by Status
completed133%
not_yet_recruiting267%
Recent Activity
0 active trials
Showing 3 of 3
not_yet_recruitingphase_3
Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma
NCT02864888
not_yet_recruitingphase_3
Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma
NCT02887040
completedphase_2
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
NCT00003473
Clinical Trials (3)
Showing 3 of 3 trials
NCT02864888Phase 3
Effect of Antineoplaston Therapy on the QT/QTc Interval In Subjects With Diffuse, Intrinsic, Brainstem Glioma
NCT02887040Phase 3
Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma
NCT00003473Phase 2
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Mixed Gliomas
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3